NSE: GRANULES | BSE: 532482

Mid-range Performer

Download real time

531.80 14.80 (2.86%)

26.02% Gain from 52W Low

503.6K NSE+BSE Volume

NSE 01 Oct, 2025 10:36 AM (IST)

12,905.1

Market Cap

High in industry

1.4

Beta 1Year

Very High Volatility

Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Search Inside the pdf :

Granules India Ltd.

18 Sep 2025

531.80

2.86%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

We remain positive on Granules' long-term growth and profitability, supported by new product launches across geographies, a focus on backward integration, and rising market share. Entry into the CDMO segment via the Senn acquisition, along with higher-margin oncology filings, is expected to strengthen financials. Moreover, resolution of regulatory issues at the Gagilapur facility could act as a key re-rating catalyst. Hence, we maintain an Accumulate rating on the...

Granules India Ltd. has an average target of 615.75 from 4 brokers.

Granules India Ltd.

22 Aug 2025

531.80

2.86%

Modest Q1FY26 growth; facility ramp-up to drive recovery

Buy: Granules India Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -0.6%/-4.6% primarily to reflect a more gradual post-remediation ramp-up at Gagillapur, and a measured margin recovery amid persistent integration and operating costs.

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

06 Jun 2025

531.80

2.86%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Validation activities have begun in Phase 2, Genome Valley, in this quarter. Also, the company continues to invest in research and development efforts aimed at building a pipeline of high-value molecules, with a focus on backward integration, especially in the oncology and CNS segment. The company has filed its first oncology molecule in this quarter....

Geojit BNP Paribas increased Accumulate price target of Granules India Ltd. to 630.0 on 18 Sep, 2025.

Granules India Ltd.

28 May 2025

531.80

2.86%

Broadly in-line quarter; margin resilience led by FDF

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered a slightly better-than-expected revenue in 4QFY25. However, it reported largely in-line EBITDA/PAT for the quarter.

Geojit BNP Paribas increased Accumulate price target of Granules India Ltd. to 630.0 on 18 Sep, 2025.

Granules India Ltd.

17 Feb 2025

531.80

2.86%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

25 Jan 2025

531.80

2.86%

Finished dosages remain the key earnings driver

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered better-than-expected revenue, while EBITDA/PAT stood in line for the quarter. The traction in finished dosage (FDF) remained robust for six quarters now.

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

06 Nov 2024

531.80

2.86%

Plants Resuming Operations and Upcoming Product Launches

Buy: Granules India Ltd.

Target

Sharekhan

Revenues stood at Rs. 957 crore, falling 19% y-o-y and 18% q-o-q, falling 5% short of our estimates.

Granules India Ltd. has an average target of 615.75 from 4 brokers.

Granules India Ltd.

12 Sep 2024

531.80

2.86%

Gagillapur site under a cloud

Buy: Granules India Ltd.

Motilal Oswal

Granules India (GRAN) was issued a Form 483 with six observations for its Gagillapur site after a recent USFDA inspection.

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

16 Aug 2024

531.80

2.86%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

31 Jul 2024, 12:00AM

531.80

2.86%

FD and low base doubled earnings YoY

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) posted in-line revenue in 1QFY25. However, it delivered better-than-estimated 1QFY25 EBITDA/PAT led by the increased share of formulation sales.

Granules India Ltd. is trading above all available SMAs

Is Granules India Ltd. worth buying?

865 Votes:

Buy 84.05%

Sell 10.17%

Hold 5.78%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf